LBTSF Quote, Financials, Valuation and Earnings

Laboratorios Farmaceúticos Rovi SA has a net margin of 1.82% compared to Almirall SA's net margin of 19.53%. Almirall SA's return on equity of 1.39% beat Laboratorios Farmaceúticos Rovi SA's return on equity of 23.25%.

Almirall SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Laboratorios Farmaceúticos Rovi SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Almirall SA has higher upside potential than Laboratorios Farmaceúticos Rovi SA, analysts believe Almirall SA is more attractive than Laboratorios Farmaceúticos Rovi SA.

Almirall SA has a beta of 0.230, which suggesting that the stock is 77.011% less volatile than S&P 500. In comparison Laboratorios Farmaceúticos Rovi SA has a beta of -737.543, suggesting its less volatile than the S&P 500 by 73854.335%.

Almirall SA has a quarterly dividend of $0.21 per share corresponding to a yield of 1.34%. Laboratorios Farmaceúticos Rovi SA offers a yield of 1.66% to investors and pays a quarterly dividend of $1.09 per share. Almirall SA pays 310.63% of its earnings as a dividend. Laboratorios Farmaceúticos Rovi SA pays out 28.3% of its earnings as a dividend. Laboratorios Farmaceúticos Rovi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Almirall SA's is not.

Almirall SA quarterly revenues are $311.1M, which are larger than Laboratorios Farmaceúticos Rovi SA quarterly revenues of $254.2M. Almirall SA's net income of $5.6M is lower than Laboratorios Farmaceúticos Rovi SA's net income of $49.6M. Notably, Almirall SA's price-to-earnings ratio is 63.35x while Laboratorios Farmaceúticos Rovi SA's PE ratio is 20.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Almirall SA is 2.63x versus 3.99x for Laboratorios Farmaceúticos Rovi SA. Usually stocks with elevated PS ratios are considered overvalued.

Oryzon Genomics SA has a net margin of 1.82% compared to Almirall SA's net margin of --. Almirall SA's return on equity of 1.39% beat Oryzon Genomics SA's return on equity of -2.63%.

Almirall SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Oryzon Genomics SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Almirall SA has higher upside potential than Oryzon Genomics SA, analysts believe Almirall SA is more attractive than Oryzon Genomics SA.

Almirall SA has a beta of 0.230, which suggesting that the stock is 77.011% less volatile than S&P 500. In comparison Oryzon Genomics SA has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.61%.

Almirall SA has a quarterly dividend of $0.21 per share corresponding to a yield of 1.34%. Oryzon Genomics SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Almirall SA pays 310.63% of its earnings as a dividend. Oryzon Genomics SA pays out -- of its earnings as a dividend.

Almirall SA quarterly revenues are $311.1M, which are larger than Oryzon Genomics SA quarterly revenues of --. Almirall SA's net income of $5.6M is higher than Oryzon Genomics SA's net income of -$1.6M. Notably, Almirall SA's price-to-earnings ratio is 63.35x while Oryzon Genomics SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Almirall SA is 2.63x versus 440.67x for Oryzon Genomics SA. Usually stocks with elevated PS ratios are considered overvalued.

Pharma Mar SA has a net margin of 1.82% compared to Almirall SA's net margin of 65.95%. Almirall SA's return on equity of 1.39% beat Pharma Mar SA's return on equity of 36.44%.

Almirall SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Pharma Mar SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Almirall SA has higher upside potential than Pharma Mar SA, analysts believe Almirall SA is more attractive than Pharma Mar SA.

Almirall SA has a beta of 0.230, which suggesting that the stock is 77.011% less volatile than S&P 500. In comparison Pharma Mar SA has a beta of 0.651, suggesting its less volatile than the S&P 500 by 34.947%.

Almirall SA has a quarterly dividend of $0.21 per share corresponding to a yield of 1.34%. Pharma Mar SA offers a yield of 1.4% to investors and pays a quarterly dividend of $0.92 per share. Almirall SA pays 310.63% of its earnings as a dividend. Pharma Mar SA pays out 18.83% of its earnings as a dividend. Pharma Mar SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Almirall SA's is not.

Almirall SA quarterly revenues are $311.1M, which are larger than Pharma Mar SA quarterly revenues of $105.3M. Almirall SA's net income of $5.6M is lower than Pharma Mar SA's net income of $69.4M. Notably, Almirall SA's price-to-earnings ratio is 63.35x while Pharma Mar SA's PE ratio is 19.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Almirall SA is 2.63x versus 6.68x for Pharma Mar SA. Usually stocks with elevated PS ratios are considered overvalued.